Investor Relations
PURE Bioscience (NASDAQ: PURE) develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Corporate Fact Sheet
First Quarter Results Conference Call: December 15, 2011
PURE Bioscience Common Stock is listed on NASDAQ.
Stock Quote: PURE
Inquiries about stock accounts, dividends or change in name or address may be directed to PURE Bioscience's stock transfer agent:
Computershare Trust Company
350 Indiana Street, Suite 800
Golden,Co 80401
1.303.262.0600
Other investor inquires may be directed to:
Don Markley, Senior Vice President
Lippert/Heilshorn & Associates
(310) 691-7100 dmarkley@lhai.com
Receive Report Materials Electronically
Shareholders may opt for the convenience of electronic shareholder materials. Subscribers receive messages containing links to the online annual report and proxy statement, and may vote their proxies online. Interested shareholders may sign up here.